SCHEMBL5656560

SCHEMBL5656560

COc1ccc(Cl)cc1Nc1ccc(Cl)cc1[N+](=O)[O-]

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.57
MEN1 O00255 3/20 0.57
KMT2A Q03164 3/20 0.57
L3MBTL1 Q9Y468 2/20 0.57
HPGD P15428 1/20 0.57
LMNA P02545 2/20 0.55
KDM4E B2RXH2 1/20 0.55
ALOX12 P18054 1/20 0.55
G6PD P11413 1/20 0.54
CRHBP P24387 1/20 0.54
CRHR2 Q13324 1/20 0.54
ALDH1A1 P00352 3/20 0.53
SMN1; SMN2 Q16637 2/20 0.53
NPSR1 Q6W5P4 1/20 0.49
PKM P14618 1/20 0.48
TDP1 Q9NUW8 1/20 0.48
AKR1C3 P42330 1/20 0.47
AKR1C2 P52895 1/20 0.47
POLB P06746 1/20 0.47
TP53 P04637 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9121900 0.92 MAPT (0.65) MAPTMEN1KMT2AL3MBTL1HPGD
SCHEMBL9117636 0.89 MAPT (0.62) MAPTMEN1KMT2AL3MBTL1HPGD
SCHEMBL9119799 0.88 EPAS1 (0.57) MAPTMEN1KMT2AHPGDLMNA
SCHEMBL9119530 0.84 MAPK1 (0.51) MAPTMEN1KMT2ALMNAKDM4E
SCHEMBL29485957 0.81 LMNA (0.59) MAPTMEN1KMT2AHPGDLMNA
SCHEMBL1119379 0.81 LMNA (0.59) MAPTMEN1KMT2AHPGDLMNA
SCHEMBL23565733 0.81 KMT2A (0.61) MEN1KMT2AHPGDLMNAALDH1A1
SCHEMBL4932340 0.79 MAPT (0.73) MAPTMEN1KMT2AL3MBTL1HPGD
SCHEMBL16485908 0.78 MAPT (0.48) MAPTMEN1KMT2AL3MBTL1HPGD
SCHEMBL9888489 0.78 AKR1C3 (0.60) MAPTMEN1KMT2AL3MBTL1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7244756-B2 Benzimidazol-2-one derivatives and their use POSEIDON PHARMACEUTICALS A/S (DK) 2007-07-17 US disclosed
US-20050250832-A1 For increasing blood-brain barrier permeability ANIONA APS (DK) 2005-11-10 US disclosed
EP-1519923-A1 NOVEL BENZIMIDAZOL-2-ONE DERIVATIVES AND THEIR USE Poseidon Pharmaceuticals A/S (DK) 2005-04-06 EP disclosed
WO-2004002962-A1 NOVEL BENZIMIDAZOL-2-ONE DERIVATIVES AND THEIR USE POSEIDON PHARMACEUTICALS A/S (DK) 2004-01-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050250832-A1 For increasing blood-brain barrier permeability FABP7, AQP4, SLC2A2 MAPT 1119/4885MEN1 3793/4885KMT2A 3967/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.